Tag: pubmed

Clin Neuropharmacol. 2024 Nov 25. doi: 10.1097/WNF.0000000000000618. Online ahead of print.

ABSTRACT

OBJECTIVES: Traditional antidepressant therapy is associated with an inadequate response and a low remission rate. Our aim was to synthesize published randomized controlled trials on the potential effects of minocycline in patients with depression.

METHODS: PubMed, Web of Science, Embase, and Cochrane Library databases were searched for studies published. Randomized controlled trials published in English that evaluated the efficacy of minocycline in patients with depression were selected for inclusion. Changes from baseline in the Hamilton Depression Rating Scale (HDRS) or Montgomery-Åsberg Depression Rating Scale (MADRS) were pooled to determine the antidepressant effect of minocycline compared with placebo. The quality of the included studies was assessed using the Cochrane risk-of-bias tool.

RESULTS: Eight trials with 567 participants were eligible and included in the analysis. The meta-analysis did not reveal a statistically significant effect of minocycline on depression based on HDRS or MADRS scores.

CONCLUSIONS: According to the HDRS and MADRS scores, minocycline did not demonstrate effectiveness in reducing depressive symptoms.

PMID:39591510 | DOI:10.1097/WNF.0000000000000618

J Stud Alcohol Drugs. 2024 Nov 26. doi: 10.15288/jsad.24-00104. Online ahead of print.

ABSTRACT

OBJECTIVE: An inability to correctly perceive chemosensory stimuli can lead to a poor quality of life. Such defects can be concomitant with excess alcohol consumption, but a large-scale cohort study linking these effects is lacking. This study aimed to investigate the impact of chronic alcohol consumption on chemosensory function by analyzing data from the NHANES 2013-2014, involving 395 participants categorized by alcohol intake behavior: 219 no-intake, 136 light-intake, and 40 risky-intake groups.

METHODS: Chemosensory function was assessed using a self-reported Chemosensory Questionnaire along with objective tests for taste (quinine solution) and smell (appetitive and hazardous odors). Adjusted regression analyses were conducted, controlling for age, gender, smoking status, and multiple pairwise comparisons. Weighted regression analyses were also performed.

RESULTS: Risky drinkers had significantly lower odds of identifying quinine (bitter taste) compared to light drinkers (OR = 0.37, p-adjusted = 0.04). Risky drinkers also had higher odds of identifying appetitive odors like strawberry (OR = 5.44, p-adjusted = 0.03) but lower odds for detecting hazardous odors like natural gas (OR = 0.11, p-adjusted = 0.001) compared to light drinkers. Additionally, light drinkers identified the leather scent more effectively than no drinkers (OR = 2.54, p = 0.02).

CONCLUSIONS: Chronic alcohol consumption, particularly at risky levels, is associated with altered chemosensory function. These findings emphasize the importance of assessing chemosensory symptoms in individuals with alcohol-related behaviors.

PMID:39589797 | DOI:10.15288/jsad.24-00104

J Stud Alcohol Drugs. 2024 Nov 26. doi: 10.15288/jsad.24-00003. Online ahead of print.

ABSTRACT

OBJECTIVE: Personalized normative feedback interventions show efficacy in reducing health risk behaviors (e.g., alcohol use, sexual aggression). However, complex personalized normative feedback interventions may require manual methods of inputting participant data into graphics, which introduces error, and automated approaches require substantial technical costs and funding and may limit the types of feedback that can be provided.

METHOD: To make personalized normative feedback more accessible, we outline a method of using easily accessible software programs including IBM Statistical Package for the Social Sciences (SPSS), Microsoft Excel, and Microsoft PowerPoint, to create and display complex personalized normative feedback graphics. We also describe methods through which personalized normative feedback graphics can be created within a larger preventive intervention for alcohol and sexual assault in college men.

RESULTS: We first provide step-by-step instructions for collecting data and then creating semi-automated syntax files within SPSS and Excel to merge participant data into complex personalized normative feedback graphics in Excel. To do so, we append annotated syntax in text and in supplemental material. Next, we outline the process of creating risk feedback graphics, whereby individual items or exact wording of items are displayed back to the participant. Finally, we provide guidance regarding the process of translating graphics from Excel for viewing via PowerPoint without having to manually update PowerPoint slides for each presentation.

CONCLUSIONS: Via the described syntax and graphic generation, researchers are then able to create semi-automated personalized normative feedback and risk feedback graphics. This tutorial may help in increasing the dissemination of complex personalized normative feedback interventions.

PMID:39589790 | DOI:10.15288/jsad.24-00003

Am J Hypertens. 2024 Nov 26:hpae147. doi: 10.1093/ajh/hpae147. Online ahead of print.

ABSTRACT

BACKGROUND: Lercanidipine, a newer-generation calcium channel blocker, is recognized for its effective antihypertensive properties and reduced side effects. This study aims to compare the effectiveness of lercanidipine and amlodipine in preventing major adverse cardiovascular events (MACE) in hypertensive patients.

METHODS: A multicenter, retrospective observational study was conducted using the electronic medical records database from three tertiary hospitals in South Korea between 2017 and 2021. Hypertensive patients treated with either amlodipine or lercanidipine were analyzed. Propensity score matching (PSM) was utilized to minimize confounders, matching patients in a 3:1 ratio. The primary endpoint was the incidence of MACE, a composite of cardiovascular death, myocardial infarction, stroke, heart failure hospitalizations, and coronary revascularization over a 3-year follow-up period.

RESULTS: A total of 47640 patients were evaluated, and 6029 patients were matched. Before PSM, the lercanidipine group had a higher cardiovascular risk (SCORE-2/SCORE-2OP value: 11.6% ± 9.2 vs 10.9% ± 8.8, p<0.01) and a higher incidence of MACE compared to the amlodipine group (4.1% vs 3.4%, p<0.01). After PSM, the incidence of MACE was numerically lower in the lercanidipine group compared to the amlodipine group (2.8% vs 4.1%, p=0.11), though this difference was not statistically significant. Blood pressure control remained comparable between the two groups over the 3-year follow-up period.

CONCLUSIONS: Lercanidipine demonstrated comparable effectiveness to amlodipine in preventing MACE among hypertensive patients. Given its comparable antihypertensive efficacy and potential for fewer side effects based on prior studies, lercanidipine may be considered a preferable option for hypertension management.

PMID:39589752 | DOI:10.1093/ajh/hpae147

JAMA Netw Open. 2024 Nov 4;7(11):e2447335. doi: 10.1001/jamanetworkopen.2024.47335.

ABSTRACT

IMPORTANCE: The kidney transplant (KT) evaluation process is particularly time consuming and burdensome for Black patients, who report more discrimination, racism, and mistrust in health care than White patients. Whether alleviating patient burden in the KT evaluation process may improve perceptions of health care and enhance patients’ experiences is important to understand.

OBJECTIVE: To investigate whether Black and White participants would experience improvements in perceptions of health care after undergoing a streamlined, concierge-based approach to KT evaluation.

DESIGN, SETTING, AND PARTICIPANTS: This prospective cohort study from a single urban transplant center included Black and White English-speaking adults who were referred for KT and deemed eligible to proceed with the KT evaluation process. The patients responded to baseline and follow-up questionnaires. The study was conducted from May 2015 to June 2018. Questionnaires were collected before KT evaluation initiation (baseline) and after KT evaluation completion (follow-up). Data were analyzed from October 2022 to January 2024.

EXPOSURE: Data were stratified by race (Black compared with White) and time (baseline compared with follow-up).

MAIN OUTCOMES AND MEASURES: The main outcomes were experiences of discrimination in health care, perceived racism in health care, medical mistrust of health care systems, and trust in physician. Repeated-measures regression was used to assess race, time, and the race-by-time interaction as factors associated with each outcome.

RESULTS: The study included 820 participants (mean [SD] age, 56.50 [12.93] years; 514 [63%] male), of whom 205 (25%) were Black and 615 (75%) were White. At baseline and follow-up, Black participants reported higher discrimination (119 [58%]; χ21 = 121.89; P < .001 and 77 [38%]; χ21 = 96.09; P < .001, respectively), racism (mean [SD], 2.73 [0.91]; t290.46 = 7.77; P < .001 and mean [SD], 2.63 [0.85]; t296.90 = 7.52; P < .001, respectively), and mistrust (mean [SD], 3.32 [0.68]; t816.00 = 7.29; P < .001 and mean [SD], 3.18 [0.71]; t805.00 = 6.43; P < .001, respectively) scores but lower trust in physician scores (mean [SD], 3.93 [0.65]; t818.00 = -2.01; P = .04 and mean [SD], 3.78 [0.65]; t811.00 = -5.42; P < .001, respectively) compared with White participants. All participants experienced statistically significant reductions in discrimination (Black participants: odds ratio, 0.27 [95% CI, 0.16-0.45]; P < .001; White participants: odds ratio, 0.37 [95% CI, 0.25-0.55]; P < .001) and medical mistrust in health care (Black participants: β [SE], -0.16 [0.05]; P < .001; White participants: β [SE], -0.09 [0.03]; P < .001), and Black participants reported lower perceived racism at follow-up (β [SE], -0.11 [0.05]; P = .04). There was a statistically significant race-by-time interaction outcome in which Black participants’ trust in physicians was significantly lower at follow-up, but White participants reported no change.

CONCLUSIONS AND RELEVANCE: The findings of this cohort study of patients who underwent a streamlined, concierge-based KT evaluation process suggest that a streamlined approach to clinic-level procedures may improve patients’ perceptions of the health care system but may not improve their trust in physicians. Future research should determine whether these factors are associated with KT outcome, type of KT received, and time to KT.

PMID:39589742 | DOI:10.1001/jamanetworkopen.2024.47335

JAMA Netw Open. 2024 Nov 4;7(11):e2447352. doi: 10.1001/jamanetworkopen.2024.47352.

ABSTRACT

IMPORTANCE: Recent evolutions in clinical care and remote monitoring suggest that some acute illnesses no longer require intravenous therapy and inpatient hospitalization.

OBJECTIVE: To describe outcomes of patients receiving care in a new, outpatient, virtual, home-based acute care model called Safer@Home.

DESIGN, SETTING, AND PARTICIPANTS: This retrospective cohort analysis, conducted from September 1, 2022, through August 31, 2023, included 2466 patients treated at a safety net hospital in Los Angeles County for 10 core illnesses and 24 other acute illnesses for which patients are commonly hospitalized.

EXPOSURE: Outpatient, home-based, acute care with virtual monitoring and clinic visits in lieu of inpatient or in-home care.

MAIN OUTCOMES AND MEASURES: The primary measure was hospital length of stay. Secondary measures included all-cause mortality, 30-day readmission, return urgent care visit rates, and return emergency department (ED) visit rates.

RESULTS: Safer@Home provided care to 876 patients (mean [SD] age, 54.0 [14.5] years; 541 men [61.8%]) during the study period, compared with a cohort of 1590 patients (mean [SD] age, 52.3 [19.6] years; 901 men [56.7%]) with matching diagnoses who received standard, hospital-based care. Safer@Home patients had significantly shorter mean (SD) lengths of inpatient stay than the comparison cohort (1.3 [2.0] vs 5.3 [10.4] days; P < .001), totaling 3505 bed-days avoided (mean [SD], 4.0 [10.6] bed-days saved per patient), with no significant difference in all-cause mortality at last follow-up (2.6% [23 of 876] vs 4.0% [64 of 1590]; P = .07). Safer@Home patients and control patients also had no significant difference in the proportion experiencing 30-day hospital readmission (19.9% [174 of 876] vs 16.7% [266 of 1590]; P = .06). As intended, more Safer@Home than control patients had at least one 30-day return urgent care visit (37.3% [327 of 876] vs 5.2% [82 of 1590]; P < .001). In contrast, the Safer@Home and control cohorts did not significantly differ in experiencing at least one 30-day return ED visit (15.2% [133 of 876] vs 12.5% [199 of 1590]; P = .06). Safer@Home patients had significantly fewer mean (SD) total 30-day return ED visits per patient than control patients (0.19 [0.50] vs 0.21 [0.85]; P < .001).

CONCLUSIONS AND RELEVANCE: In this cohort study, patients receiving acute, virtual, home care with remote monitoring and as-needed return urgent care visits had markedly shorter hospital stays than patients receiving standard inpatient hospital care, with no significant increase in mortality, ED revisits, or return hospitalizations. This new care model is promising for systems that cannot staff Medicare-compliant hospital-at-home visits.

PMID:39589741 | DOI:10.1001/jamanetworkopen.2024.47352

JAMA Netw Open. 2024 Nov 4;7(11):e2447635. doi: 10.1001/jamanetworkopen.2024.47635.

ABSTRACT

IMPORTANCE: Disparities in minoritized racial and ethnic populations’ participation in gynecologic cancer clinical trials are well documented despite the high rates of endometrial cancer in these populations. Geographic proximity to trials is a critical component to ensure equitable trial access.

OBJECTIVE: To characterize the geographic distribution of gynecological cancer trials across the US and identify disparities.

DESIGN, SETTING, AND PARTICIPANTS: This study is a cross-sectional analysis of trials first posted on ClinicalTrials.gov from January 1, 2013, through January 10, 2024. This study involved a state-level analysis of clinical trials located in the US. Enrollment criteria of clinical trials for ovarian, uterine, cervical, endometrial, vaginal and/or vulvar, and other gynecological cancers were reviewed to exclude nongynecological cancers (1643 trials) or noninvasive gynecological conditions (224 trials).

EXPOSURE: The number of gynecological trials per 100 000 persons in each state.

MAIN OUTCOMES AND MEASURES: A state-level analysis was performed to determine whether gynecologic cancer clinical trial availability in the US is associated with other state-level characteristics to identify areas of increased need. Census data, state-level total population size, percentage of non-Hispanic White persons, and the Federal Emergency Management Agency expected annual loss per state as a measure of social vulnerability were aggregated. The association between these variables and the number of gynecological trials per 100 000 persons was measured using Spearman rank correlation.

RESULTS: Of the 1561 invasive gynecological cancer trials that met the inclusion criteria, most cancer trials were ovarian (911 trials [58.4%]), followed by cervical (438 trials [28.1%]), and endometrial (385 trials [24.7%]). Predominantly minoritized population-serving states (ie, those with <50% non-Hispanic White persons) had fewer than 4 trials per 100 000 persons, but this was not significant nationally (ρ = 0.20; 95% CI, -0.08 to 0.45; P = .16). States with higher Federal Emergency Management Agency expected annual loss had lower numbers of gynecological trials per 100 000 persons, which was significant nationally (ρ = -0.53; 95% CI, -0.70 to -0.29; P < .001).

CONCLUSIONS AND RELEVANCE: In this cross-sectional study of female gynecological cancer trials by state, states with particularly high economic vulnerability and minoritized populations had low clinical trial availability. Further efforts are needed to address disparities identified in this study to ensure equitable trial access.

PMID:39589740 | DOI:10.1001/jamanetworkopen.2024.47635

J Cancer Surviv. 2024 Nov 26. doi: 10.1007/s11764-024-01704-1. Online ahead of print.

ABSTRACT

PURPOSE: To determine the efficacy of nurse-delivered brief behavioral treatment for insomnia (BBTI) compared to an attention control, in a heterogeneous sample of cancer survivors to reduce insomnia symptom severity.

METHODS: We recruited 132 participants from cancer care clinics, who had an Insomnia Severity Index (ISI) score ≥ 8. Participants were randomized into two groups: an experimental BBTI group and a healthy eating attention control group. Demographics survey at baseline, and sleep-related questionnaires, self-reported sleep diaries, and wrist-worn actigraphy at baseline, 1, 3, and 12 months were collected. Statistical analyses used analysis of covariance (ANCOVA) models with two-sided 0.05 nominal significance level for treatment effect for primary outcome of insomnia severity at 1 month.

RESULTS: Participants were cancer survivors with a mean age of 63.7 years, 55% female, 88.6% white, with breast, prostate, colorectal, and lung cancer. Statistically significant group differences were observed at all time points for ISI and sleep quality (ISI effect sizes 0.56, 0.59, and 0.54 respectively). Additionally, at 1 month, those in insomnia remission (ISI ≤ 8) were higher for the BBTI (55.1%) compared to the control group (43.3%). Secondary outcomes from sleep diary measures (i.e., sleep efficiency, sleep onset latency, wake after sleep onset) were significant at 1 month.

CONCLUSION: The BBTI group was significantly effective in reducing insomnia severity and improving sleep quality over time compared to the control among cancer survivors.

CLINICAL TRIAL REGISTRATION: Clinical trials identifier: http://ClinicalTrials.gov , NCT03810365.

IMPLICATIONS FOR CANCER SURVIVORS: Implementing BBTI in survivorship settings can effectively address and manage insomnia symptoms, thus bridging a crucial gap in care for cancer survivors.

PMID:39589721 | DOI:10.1007/s11764-024-01704-1

Infect Dis Ther. 2024 Nov 26. doi: 10.1007/s40121-024-01073-3. Online ahead of print.

ABSTRACT

INTRODUCTION: In 2023, recombinant zoster vaccine (RZV) replaced zoster vaccine live (ZVL) vaccine in the UK National Immunisation Programme (NIP) for prevention of herpes zoster (HZ). The vaccination age was reduced from 70 to 65 years, with a subsequent planned reduction to 60 years. This modelling study aimed to evaluate the public health impact (PHI) of RZV vaccination in the 70 years of age (YOA) population and in younger individuals 65 and 60 YOA.

METHODS: PHI was evaluated from a National Health Service perspective, as cases of HZ, post-herpetic neuralgia (PHN), non-PHN complications and deaths, hospitalisations, and general practitioner (GP) visits avoided using a multicohort Markov model. Three scenarios (RZV vs. no vaccination, ZVL vs. no vaccination, and RZV vs. ZVL) were explored for each age group using population estimates from the UK Office for National Statistics, i.e. 70 YOA (n = 649,822), 65 YOA (n = 760,578) and 60 YOA (n = 849,501).

RESULTS: Modelled outcomes in 70 YOA individuals estimated that RZV vaccination would avoid 32,894 cases of HZ and 5915 cases of PHN compared with no vaccination and 26,954 HZ and 3218 PHN cases compared with ZVL. Compared with no vaccination, 2264 fewer hospitalisations and 158,549 fewer GP visits were predicted with RZV vaccination. Hospitalisations were predicted to be reduced by 1996 and GP visits by 130,821 for RZV versus ZVL vaccination. In individuals 65 YOA, it was estimated that RZV vaccination would avoid 50,128 HZ cases, 8623 PHN cases, 222,646 GP visits, and 2671 hospitalisations versus no vaccination. In the 60 YOA group, RZV vaccination was predicted to avoid 57,182 HZ cases, 9327 PHN cases, 234,330 GP visits, and 2547 hospitalisations versus no vaccination.

CONCLUSION: The recent introduction of RZV into the NIP could substantially reduce HZ disease burden and healthcare resource use in the UK. A graphical abstract is available with this article.

PMID:39589700 | DOI:10.1007/s40121-024-01073-3

Behav Genet. 2024 Nov 26. doi: 10.1007/s10519-024-10207-9. Online ahead of print.

ABSTRACT

Causal inference is inherently complex and relies on key assumptions that can be difficult to validate. One strong assumption is population homogeneity, which assumes that the causal direction remains consistent across individuals. However, there may be variation in causal directions across subpopulations, leading to potential heterogeneity. In psychiatry, for example, the co-occurrence of disorders such as depression and substance use disorder can arise from multiple sources, including shared genetic or environmental factors (common causes) or direct causal pathways between the disorders. A patient diagnosed with two disorders might have one recognized as primary and the other as secondary, suggesting the existence of different types of comorbidity. For example, in some individuals, depression might lead to substance use, while in others, substance use could lead to depression. We account for potential heterogeneity in causal direction by integrating the Direction of Causation (DoC) model for twin data with finite mixture modeling, which allows for the calculation of individual-level likelihoods for alternate causal directions. Through simulations, we demonstrate the effectiveness of using the Direction of Causation Twin Mixture (mixDoC) model to detect and model heterogeneity due to varying causal directions.

PMID:39589697 | DOI:10.1007/s10519-024-10207-9